<div><div></div><div><span><ul><li><span>According to estimates from 12 analysts, Bio-Techne Corp stock's average price target has risen from $65.33 to $66.42, with forecasts ranging from $50 to $75 per share</span></li><li><span>Based on the Jun. 24 closing price, the updated target implies approximately 13% potential upside</span></li><li><span>Consensus rating remains at “Buy” across 19 covering analysts, with 11 Buys, 7 Holds and 1 Sells</span></li></ul><p><span>Explore more price target data and ratings for Bio-Techne Corp on the </span><span>, and track all previous and future analyst recommendations for Bio-Techne Corp in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

TECH

<p>Bio-Techne Corp's average 12-month price target has been raised to $66.42 by 12 analysts, up from $65.33, implying a 13% upside based on the June 24 closing price. The consensus rating remains 'Buy' across 19 covering analysts, with forecasts ranging from $50 to $75 per share.</p>

Bio-Techne Corp Stock 12‑Month Price Target Raised to $66.42, Implies 13% Upside